Discovery of a link between T cell ageing and metabolism by the Founder (Lanna et al. Nature Immunology 2014)
January 2017
Identification of sMAC (Sestrin MAP kinase activation complex) as a multi-druggable longevity target (Lanna et al. Nature Immunology 2017)
May 2019
Establishment of Sentcell Ltd to translate the sMAC discovery into longevity (rejuvenating and anti-ageing) therapies following seed investment
April 2021
Series A funding to support IMPD application for first in human (FIH) DOS46L rejuvenating program and sMAC pipeline expansion
December 2021
International Patent Cooperation Treaty (PCT) filing for "Sestrin-MAP kinase complex inhibitors" describing synthesis of first in class disruptors of sMAC and their use to treat age-related diseases
June 2022
Recognition of DOS as a new immune rejuvenating class by the Indian Health Authorities
July 2022
Successful Preliminary Regulatory Meeting with the Medicine & Healthcare Products Regulatory Agency (MHRA, UK) to support FIH DOS46L clinical program
August 2022
Discovery of telomere transfer as a new anti-ageing intervention (Lanna et al. Nature Cell Biology)
Browse our history
We develop first-in class compounds to achieve human rejuvenation.
